UBS/CALL/ELI LILLY & CO/630/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 01:31:46 2024-07-12 pm EDT | ||
| 29.71 EUR | +5.69% |
|
| Current month | +7.92% | ||
| 1 month | +26.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 29.71 | +5.69% |
| 24-07-11 | 28.11 | -3.40% |
| 24-07-10 | 29.1 | +3.89% |
| 24-07-09 | 28.01 | +3.51% |
| 24-07-08 | 27.06 | +0.59% |
Delayed Quote Deutsche Boerse AG
Last update July 12, 2024 at 01:31 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| WKN | UL8LNJ |
| ISIN | CH1294722447 |
| Date issued | 2023-09-07 |
| Strike | 630 $ |
| Maturity | 2024-09-20 (70 Days) |
| Parity | 10 : 1 |
| Emission price | 4.19 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 29.89 € |
|---|---|
| Lowest since issue | 3.23 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
948.4
USD
Average target price
894.8
USD
Spread / Average Target
-5.65%
- Stock Market
- Warrants
- Warrant
